News 12.03.2024 Press Release Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis Read More 09.08.2024 Publication RESOLVE-Lung, a multinational Phase II, randomized, placebo-controlled trial of namilumab in chronic pulmonary sarcoidosis: Trial design and patient characteristics Read More 05.06.2024 Podcast Kinevant Sciences makes progress with its drug Namilumab Listen on Apple Podcasts Listen on Spotify 04.24.2024 Press Release Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis Read More 11.17.2022 Press Release Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung) Read More 08.29.2022 Podcast Sarc Fighter: Living with Sarcoidosis and other rare diseases Listen on Apple Podcasts Listen on Spotify
